Complex Oncological Center Plovdiv EOOD Dept of Med Oncology and Oncological Diseases in Hematology

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Head and neck cancer

Running trials

• Recruiting

  Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)

  NCT06295731· Phase 2/3· Inhibrx Biosciences, Inc· Source

  Contact: Study Director - Inhibrx